Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPC3 | Q13507 | 10/20 | 1.00 |
| ▸ | TRPC6 | Q9Y210 | 10/20 | 1.00 |
| ▸ | TRPA1 | O75762 | 2/20 | 1.00 |
| ▸ | CACNA1C | Q13936 | 2/20 | 1.00 |
| ▸ | SCN5A | Q14524 | 2/20 | 1.00 |
| ▸ | TRPV1 | Q8NER1 | 2/20 | 1.00 |
| ▸ | TRPV4 | Q9HBA0 | 2/20 | 1.00 |
| ▸ | HCRTR1 | O43613 | 10/20 | 0.41 |
| ▸ | HCRTR2 | O43614 | 4/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL798463 | 1.00 | TRPC3 (1.00) | TRPC3TRPC6TRPA1CACNA1CSCN5A | |
| SCHEMBL30186173 | 1.00 | TRPC3 (1.00) | TRPC3TRPC6TRPA1CACNA1CSCN5A | |
| SCHEMBL26458205 | 0.91 | TRPC3 (0.83) | TRPC3TRPC6TRPA1CACNA1CSCN5A | |
| SCHEMBL26458213 | 0.91 | TRPC3 (0.83) | TRPC3TRPC6TRPA1CACNA1CSCN5A | |
| SCHEMBL789038 | 0.87 | TRPC3 (0.77) | TRPC3TRPC6TRPA1CACNA1CSCN5A | |
| SCHEMBL790188 | 0.84 | TRPC3 (0.72) | TRPC3TRPC6TRPA1CACNA1CSCN5A | |
| SCHEMBL806600 | 0.84 | TRPC3 (1.00) | TRPC3TRPC6TRPA1CACNA1CSCN5A | |
| SCHEMBL26459144 | 0.84 | TRPC3 (0.72) | TRPC3TRPC6TRPA1CACNA1CSCN5A | |
| SCHEMBL790044 | 0.83 | TRPC3 (0.71) | TRPC3TRPC6TRPA1CACNA1CSCN5A | |
| SCHEMBL806708 | 0.81 | TRPC3 (0.68) | TRPC3TRPC6TRPA1CACNA1CSCN5A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230137816-A1 | ADMINISTRATION OF CALCIUM CHANNEL TRPC6 INHIBITORS USING BALLOONS, STENTS OR OTHER MEDICAL DEVICES | DEUTSCHES HERZZENTRUM MUENCHEN DES FREISTAATES BAYERN (DE) | 2023-05-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230137816-A1 | ADMINISTRATION OF CALCIUM CHANNEL TRPC6 INHIBITORS USING BALLOONS, STENTS OR OTHER MEDICAL DEVICES | TRPC6, TRPC1, ORAI1 | TRPC3 6/4885TRPC6 1/4885TRPA1 26/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.